ClinicalTrials.gg
Not yet recruitingNCT05848934Updated May 8, 2023

Research on the Relationship Between Cognitive Function Changes and Cerebrovascular Health in Patients With Coronary Heart Disease

An observational study in Coronary Heart Disease and Image, sponsored by Nanjing University of Traditional Chinese Medicine. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-08.

Sponsored by Nanjing University of Traditional Chinese Medicine · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
40 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to elucidate the imaging mechanisms of cognitive function changes in patients with coronary heart disease before and after surgery or conservative treatment, and to evaluate and predict the postoperative neurological function recovery and cerebrovascular health level of patients by combining serum markers and patient cardiovascular health evaluation indicators.

Read the detailed description

The focus of this study is to elucidate the impact of coronary heart disease on the morphology and cognitive changes of cerebral blood vessels in patients. Record imaging data, neuropsychological cognitive scales, serum markers, adverse cardiac events, and patient evaluation indicators before and after clinical treatment and follow-up period, and explore relevant factors affecting changes in cerebrovascular morphology and cognitive function.

02

Conditions studied

  • Coronary Heart Disease
  • Image

Browse trials for

Keywords

  • Coronary Heart Disease
  • MRI Imaging
  • Neuropsychological assessment
03

In context

Coronary Disease

1,520 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

This study's planned enrollment of 100 is below the median of 916 across 478 observational studies indexed under Coronary Disease.

Browse Coronary Disease studies →

Lead sponsor

Nanjing University of Traditional Chinese Medicine is the lead sponsor of 17 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All of the patients of CAD(coronary heart disease )surgical treatment group and CAD(coronary heart disease )conservative treatment group are in-patients and out-patients in the cardiac surgery department from the research center. The subjects of healthy control group are recruited from community.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed coronary heart disease or risk of coronary heart disease through clinical testing
  • Conscious and capable of completing neuropsychological scales

Exclusion criteria

Exclusion Criteria:

  • Patients with other serious heart diseases (such as aortic aneurysm)
  • People with uncontrolled hypertension or diabetes
  • There are to MRI examination (there are metal implants in the body, such as cardiac pacemakers, metal dentures, artificial joints, non paramagnetism stents, etc.; there is claustrophobia)
  • Have a history of severe stroke, epilepsy, traumatic brain injury, and transient ischemic events
  • Existence of neurological and mental disorders (schizophrenia, depression, etc.), post-traumatic stress disorder, obsessive-compulsive disorder, multiple sclerosis, amyotrophic lateral sclerosis, etc
  • Have a history of alcohol or drug abuse
  • Those with significant organ dysfunction such as lung, liver, and kidney;
  • Patients with tumor, infectious diseases, blood system disease and immune system disease;
  • Currently participating in other clinical studies at the same time.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • CAD(coronary heart disease )surgical treatment

    Device: magnetic resonance image · Diagnostic Test: Neuropsychological scale

  • CAD(coronary heart disease )conservative treatment

    Device: magnetic resonance image · Diagnostic Test: Neuropsychological scale

  • HC (Healthy controls)

    Device: magnetic resonance image · Diagnostic Test: Neuropsychological scale

Interventions

  • Devicemagnetic resonance image

    Imaging data were collected in a strong magnetic field

  • Diagnostic testNeuropsychological scale

    Multi dimensional neuropsychological test

06

What researchers measure

Primary outcomes

  1. Change of brain volume before and after treatment

    The change of brain volume (mm3) are evaluated by structural 3DT1 weighted MRI. Freesurfer software is used to get the measured value of the volume.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  2. Change of cerebrovascular morphology before and after treatment

    The change of Cerebral vessel density, caliber and tortuosity, brain white matter hyperintensity lesion count

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  3. Change of brain function connectivity before and after operation

    The change of brain functional connectivity intensity are evaluated by rest stage functional MRI. DPABI software based on MATLAB is used to get the measured the matrix value of functional connectivity.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

Secondary outcomes

  1. Change of serum marker concentration before and after operation

    The change of serum marker concentration is evaluated by inflammatory cytokine.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  2. Change of plasma marker concentration before and after operation

    The change of plasma marker concentration is evaluated by neurofilament light chain(NFL) protein extracted from plasma.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  3. Change of cardiovascular risk factors before and after operation

    The change of cardiovascular risk factors is evaluated by blood routine and patients' living habits

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  4. Change of executive functions before and after operation evaluated by Trail-Making Test Part A

    The change of executive functions are first evaluated by Trail-Making Test Part A test. The minimum value is 0 , and the maximum value is 30. This test has no clear maximum and minimum values. If the test completion time exceeds 79 seconds, it means the outcome is abnormal. The higher scores mean a worse outcome.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  5. Change of working memory before and after operation evaluated by Forward Digit Span

    The change of working memory is first evaluated by Forward Digit Span. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 7.75±1.47. The higher scores mean a better outcome.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  6. Change of working memory before and after operation evaluated by Backward Digit Span

    The change of working memory is second evaluated by Backward Digit Span. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 5.36±1.91. The higher scores mean a better outcome.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  7. Change of executive functions before and after operation evaluated by Trail-Making Test Part B

    The change of executive functions are first evaluated by Trail-Making Test Part B test. The minimum value is 0 , and the maximum value is 30. This test has no clear maximum and minimum values. If the test completion time exceeds 79 seconds, it means the outcome is abnormal. The higher scores mean a worse outcome.It is a supplement to Trail-Making Test Part A, which is optional for patients who are not familiar with the English alphabetical order

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  8. Change of executive functions before and after operation evaluated by Digit Symbol Coding score

    The change of executive functions are second evaluated by Digit Symbol Coding score. The minimum value is 0 , and the maximum value is not clear. The normal range of results is 56.53 ± 20.17. The higher scores mean a better outcome.

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

  9. Change of episodic memory functions before and after operation evaluated by Auditory Verbal Learning test

    The change of episodic memory are evaluated by Auditory Verbal Learning test(AVLT-H).

    Time frame: before operation; 3-10 Days after operation; 1 month; 6-12months

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05848934
Lead sponsor
Nanjing University of Traditional Chinese Medicine
Collaborators
Xi'an Jiaotong University, Yuncheng First Hospital
Responsible party
Qianyan Liu (Principal Investgator, Nanjing University of Traditional Chinese Medicine) — Principal investigator
First posted
May 8, 2023
Start date
May 1, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 8, 2023

Study contacts

Nengrui Guo
Contact
657040251@qq.com
0086-17635599999
Lijun Bai, phD
Contact
bailijun@xjtu.edu.cn
0086-15129034948
Nengrui Guo
principal investigator · Yuncheng First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion